1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,600 | 11,200 | 21:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Pharming Group: Umsatz im Q1 2026 sinkt wegen Herausforderungen bei RUCONEST | 10 | Investing.com Deutsch | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 07.05. | Pharming GAAP EPS of $0.00 in-line, revenue of $72.4M misses by $19.67M | 10 | Seeking Alpha | ||
| 07.05. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.05. | Pharming Group N.V.: Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders | 13 | GlobeNewswire (USA) | ||
| 07.05. | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | 1.675 | GlobeNewswire (Europe) | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen | |
| 23.04. | Pharming Group N.V.: Pharming Group to report first quarter 2026 financial results and provide business update on May 7 | 472 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen | |
| 16.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.04. | Pharming Group N.V.: Pharming Group announces the 2026 Annual General Meeting of Shareholders | 352 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company's 2026 Annual General Meeting... ► Artikel lesen | |
| 07.04. | Pharming Group N.V.: Pharming Group to participate in April investor conferences | 457 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences... ► Artikel lesen | |
| 02.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 02.04. | Pharming Group N.V.: Pharming Group announces the filing of its 2025 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 27.03. | Pharming granted EU backing for rare immunodeficiency therapy | 2 | Seeking Alpha | ||
| 27.03. | Pharming Group N.V.: Pharming Group receives positive CHMP opinion for Joenja (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older | 1.151 | GlobeNewswire (Europe) | If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision... ► Artikel lesen | |
| 24.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.03. | Pharming Group N.V.: Pharming Group announces approval of Joenja (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older | 390 | GlobeNewswire (Europe) | First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients... ► Artikel lesen | |
| 12.03. | Pharming outlines $405M-$425M 2026 revenue target as Joenja and RUCONEST drive growth | 9 | Seeking Alpha | ||
| 12.03. | Wainwright bekräftigt "Kaufen"-Rating für Pharming-Aktie dank stabilem Wachstum | 7 | Investing.com Deutsch | ||
| 12.03. | Wainwright reiterates Pharming stock Buy rating on commercial growth | 2 | Investing.com | ||
| 12.03. | Pharming Group meldet Umsatz von 106,5 Mio. US-Dollar im 4. Quartal und bestätigt Prognose für 2026 | 14 | Investing.com Deutsch |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,230 | +2,95 % | KAUFKURSE bei Renk und Desert Gold! SCHOCK bei der Evotec Aktie! | Während der Goldpreis schwächelt, befindet sich die Aktie von Desert Gold in einem sauberen Aufwärtstrend. Und geht es nach Analysten, ist eine Vervielfachung möglich. Denn Desert Gold wird in wenigen... ► Artikel lesen | |
| MODERNA | 40,640 | -0,10 % | Moderna Flu Shot Heads To FDA Advisory Panel | ||
| VALNEVA | 2,501 | +0,16 % | Valneva Aktie: Prognose kassiert - die Börse schaut woanders hin | Valneva hat das erste Quartal 2026 mit einem deutlichen Umsatzrückgang abgeschlossen und die Jahresprognose gesenkt. Der Aktienkurs reagierte nicht entscheidend, denn der Markt richtet seinen Blick... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,380 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,350 | +0,75 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June | ||
| INTELLIA THERAPEUTICS | 10,920 | +2,44 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,030 | -4,63 % | PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing | MENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of sequencing solutions, and Lucid Genomics GmbH, a provider of cutting-edge bioinformatics... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,840 | +0,52 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ATAIBECKLEY | 3,780 | +1,61 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen | ||
| XOMA ROYALTY | 35,600 | -1,11 % | Ligand Pharmaceuticals und XOMA Royalty passen Fusionsvereinbarung an | ||
| CELLECTAR BIOSCIENCES | 3,270 | +3,15 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement | OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct... ► Artikel lesen | |
| NOVOCURE | 15,525 | +0,75 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,108 | -1,99 % | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,900 Euro und damit +1,87 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.